Dried plum's unique capacity to reverse bone loss and alter bone metabolism in postmenopausal osteoporosis model
- PMID: 23555991
- PMCID: PMC3612052
- DOI: 10.1371/journal.pone.0060569
Dried plum's unique capacity to reverse bone loss and alter bone metabolism in postmenopausal osteoporosis model
Abstract
Interest in dried plum has increased over the past decade due to its promise in restoring bone and preventing bone loss in animal models of osteoporosis. This study compared the effects of dried plum on bone to other dried fruits and further explored the potential mechanisms of action through which dried plum may exert its osteoprotective effects. Adult osteopenic ovariectomized (OVX) C57BL/6 mice were fed either a control diet or a diet supplemented with 25% (w/w) dried plum, apple, apricot, grape or mango for 8 weeks. Whole body and spine bone mineral density improved in mice consuming the dried plum, apricot and grape diets compared to the OVX control mice, but dried plum was the only fruit to have an anabolic effect on trabecular bone in the vertebra and prevent bone loss in the tibia. Restoration of biomechanical properties occurred in conjunction with the changes in trabecular bone in the spine. Compared to other dried fruits in this study, dried plum was unique in its ability to down-regulate osteoclast differentiation coincident with up-regulating osteoblast and glutathione (GPx) activity. These alterations in bone metabolism and antioxidant status compared to other dried fruits provide insight into dried plum's unique effects on bone.
Conflict of interest statement
Figures
References
-
- NOF (2002) America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation.
-
- The Surgeon General (2004) Bone Health and Osteoporosis: A Report of the Surgeon General. - PubMed
-
- Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274: 34967–34973. - PubMed
-
- Deal C (2004) The use of intermittent human parathyroid hormone as a treatment for osteoporosis. Curr Rheumatol Rep 6: 49–58. - PubMed
-
- Cosman F (2008) Parathyroid hormone treatment for osteoporosis. Curr Opin Endocrinol Diabetes Obes 15: 495–501. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
